Kriya Acquires Redpin Therapeutics

Kriya, a Redwood City CA, and Research Triangle Park, NC-based gene remedy firm, acquired Redpin Therapeutics, a New York-based biotechnology firm.

The quantity of the deal was not disclosed.

The acquisition serves as the inspiration for Kriya’s neurology therapeutic space portfolio, with two lead gene remedy applications centered on epilepsy and trigeminal neuralgia (TN).

Led by CEO Dr. Elma Hawkins, Redpin Therapeutics is a preclinical stage gene remedy firm growing a proprietary chemogenetics platform for focused cell therapies to handle presently intractable illnesses of the central nervous system. Its know-how makes use of gene remedy to specific engineered ion channels which are attentive to modulation by the FDA-approved anti-smoking drug varenicline to both inhibit particular overactive neurons or stimulate underactive ones. Redpin has a worldwide unique license from the Howard Hughes Medical Institute for the therapeutic use of this know-how, Investors included 4BIO Capital, Arkin Bio Ventures, Takeda Ventures Inc, New York Ventures and Alexandria Venture Investments.

Led by Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer, Kriya is an built-in firm offering applied sciences and therapeutics in gene remedy. It is advancing a deep and diversified pipeline of revolutionary gene therapies in a number of therapeutic space divisions, with present pipeline applications in metabolic problems, neurology and ophthalmology. Kriya is backed by life sciences and know-how traders, and has core operations in Silicon Valley, California and Research Triangle Park, North Carolina.



Leave a Comment